The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

NCT03324581 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

239

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Attention Deficit Hyperactivity Disorder

Interventions

DRUG: OPC-64005
DRUG: Atomoxetine
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.